Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis

<bold>Rationale:</bold> Clinical remission (CR) is an emerging composite outcome in asthma assessed after 52 weeks and includes stabilisation/optimisation of lung function (LF) as one of the components. This CAPTAIN post hoc analysis assessed the impact of different LF thresholds on a CR composite outcome in patients receiving FF/UMEC/VI or FF/VI. <bold>Methods:</bold> CAPTAIN compared FF/UMEC/VI vs FF/VI in adults with uncontrolled moderate–severe asthma despite ICS/LABA. The CR composite endpoint, defined as no systemic corticosteroid use, no severe exacerbations, ACQ-5 total score ≤1.5 and change from baseline in trough FEV₁ ≥0mL (LF stabilisation) or FEV₁ ≥100mL (LF optimisation), was assessed at Weeks 24 and 52 (w24, w52) for FF/UMEC/VI 100/62.5/25 or 200/62.5/25µg, and FF/VI 100/25 or 200/25µg. <bold>Results:</bold> A greater proportion of patients met the components of CR at w24 and achieved CR at w52 with FF/UMEC/VI vs FF/VI, regardless of LF threshold or FF dose. Stabilisation of LF vs optimisation increased the proportion of patients achieving CR (<bold>Figure</bold>). <bold>Conclusions:</bold> LF stabilisation and optimisation were attained with FF/UMEC/VI and FF/VI within the composite of CR. The relative difference between arms was consistent irrespective of LF threshold, FF dose, or timepoint. LF may be a major contributor to CR for patients with uncontrolled moderate–severe asthma not considered for biologics therapy. <bold>Funding:</bold> GSK (205715/<ext-link>NCT02924688</ext-link>) <fig><object-id>erj;64/suppl_68/PA1199/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>